CHINA BIOMEDICAL FUND PHASE I
China Biomedical Fund Phase I (general partnership) was established on November 28, 2014, registered in the British Virgin Islands and is the executive partner of China Biomedical Fund Phase I (Limited Partnership), which is numbered 1851612.
CHINA BIOMEDICAL FUND PHASE I
Founded:
2014-01-01
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-21 | Sumgen Biotech | China Biomedical Fund Phase I investment in Series A - Sumgen Biotech | N/A |
More informations about "China Biomedical Fund Phase I"
Top 50 Biotechnology VC (Venture Capital) Funds in China in
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in …See details»
‘The bar has risen’: China’s biotech gains …
Jan 16, 2025 The statistics bear Burow’s view out. According to Jefferies, the number and average value of deals for China-developed drugs reached record levels last year. Another …See details»
Investment benchmark for Asia’s biotechnology sector: CES HK
Organisation (BIO) in the US5, the likelihood of a drug candidate in Phase I clinical trials receiving final approval by the US FDA6 is merely 10%. Most candidates fail to advance from Phase II …See details»
Shanghai Zhangkeherun Biomedical RMB Fund - PitchBook
Shanghai Zhangkeherun Biomedical RMB Fund is a 2021 vintage venture capital fund managed by Shanghai Zhangjiang Science & Technology Venture Capital. Request a free trial Log in …See details»
Shanghai looking to become international hub for medical industry
Mar 11, 2025 Shanghai Pudong New Area's Zhangjiang National Innovation Demonstration Zone－a key player in China's pharmaceutical industry－has developed interactively with …See details»
E.China's Wuxi city steps up biomedical industry …
Aug 5, 2022 Photo shows 2022 Taihu Bay Future Healthcare Conference site. BEIJING, Aug. 5 (Xinhua) -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in east China's Jiangsu Province witnessed the …See details»
Novamab officially announced the completion of nearly 300 …
Shanghai, China, July 31, 2024- Shanghai Novamab Biopharmaceuticals Co., Ltd. (the "Company" or "Novamab"), a biotechnology company dedicated to the research and …See details»
Early Phase Clinical Studies in China - EBF
• GUIDELINE FOR PHASE I CLINICAL TRIAL, SFDA, Effected on Dec. 02, 2011 –Based on GCP, and the current situation of domestic Phase I trials –Referred to the relevant …See details»
China Biomedical Fund Phase I - Investments, Portfolio
Feb 21, 2019 China Biomedical Fund Phase I has invested in Sumgen Biotech on Feb 21, 2019. How many investments has this organization made over time? Show . Which industries has …See details»
U.S.-China Program for Biomedical Research Cooperation …
U.S.-China Program for Biomedical Research Cooperation Preliminary Program Review The National Institutes of Health (NIH), in collaboration with the National Natural Science …See details»
China Biomedical Fund Phase I - Crunchbase
China Biomedical Fund Phase I is an investment Fund.See details»
Life science ecosystems in Asia: biomedical innovation trends
1 day ago However, lack of public biomedical funding for academic and translational research (~$1.0 billion in 2023 for India compared with ~$8 billion for China and ~$4 billion for South …See details»
LaNova Medicines Completes USD 42 Million Series C1 Financing …
Oct 18, 2024 In the first quarter of 2024, LM-302 entered a Phase III registration clinical trial in China, making it one of the top three candidates globally in terms of development progress for …See details»
Shanghai Biomedical Industrial Equity Investment Fund
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry. New. ... Shanghai Biomedical Industrial Equity Investment …See details»
Shuki Gleitman's GIBF raising $300 million in China for second …
May 31, 2021 The Guangzhou Industrial Investment Fund, Guangzhou Pharmaceuticals Company, Guangzhou International Bio-Island, and Guangzhou Hengyun Enterprises are all …See details»
Biomedical companies seek intl growth - Chinadaily.com.cn
Sep 13, 2021 Biomedical companies seek intl growth. By ZHOU WENTING in Shanghai | China Daily | Updated: 2021-09-13 09:00 ... Innovative therapies from China benefit patients worldwide.See details»
[News] China“Big Fund” Phase II Invested in a Fab and a Silicon ...
Jul 19, 2024 “Big Fund” Phase II Invested Fab XLMEC with CNY 2.1 Billion Recently, according to the latest information from QCC, Chongqing XLMEC has undergone several industrial and …See details»
Towards government-funded special biomedical research …
Government-funded special biomedical research programs in the USA, EU, and Japan may serve as a reference for China coping with rare diseases. The government-funded special …See details»
Five Projects from Central South University Granted Funding by …
Dec 16, 2022 Recently, the China Medical Board (CMB) in the United States sent a letter to our university, announcing the successful approval of four projects under the 2023 CMB Open …See details»
LIVE NOW: ‘Abject fear’ returns to Gaza, Security Council ... - UN …
4 days ago The UN Security Council met in New York on Tuesday on the Middle East crisis, exactly two months since the start of the fragile Gaza ceasefire and hostages deal came into …See details»